NYSEAMERICAN:NAVB - Navidea Biopharmaceuticals Stock Price, Forecast & News

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) issued its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.17). The biopharmaceutical company had revenue of $0.24 million for the quarter. View Navidea Biopharmaceuticals' Earnings History.

Navidea Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Navidea Biopharmaceuticals.

2 brokerages have issued 1 year target prices for Navidea Biopharmaceuticals' shares. Their forecasts range from $2.00 to $3.00. On average, they expect Navidea Biopharmaceuticals' stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 155.1% from the stock's current price. View Analyst Price Targets for Navidea Biopharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Navidea Biopharmaceuticals.

Press coverage about NAVB stock has been trending extremely negative this week, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Navidea Biopharmaceuticals earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Navidea Biopharmaceuticals.

Navidea Biopharmaceuticals saw a drop in short interest in February. As of February 14th, there was short interest totalling 525,300 shares, a drop of 21.0% from the January 30th total of 664,900 shares. Based on an average trading volume of 157,100 shares, the short-interest ratio is currently 3.3 days. Currently, 4.7% of the company's stock are short sold. View Navidea Biopharmaceuticals' Current Options Chain.

Some companies that are related to Navidea Biopharmaceuticals include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include NovaBay Pharmaceuticals (NBY), Inovio Pharmaceuticals (INO), Opko Health (OPK), Novavax (NVAX), Rexahn Pharmaceuticals (REXN), AcelRx Pharmaceuticals (ACRX), Agenus (AGEN), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL) and Gilead Sciences (GILD).

Navidea Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Allred Capital Management LLC (0.13%). Company insiders that own Navidea Biopharmaceuticals stock include Claudine Bruck, Jed Latkin, John K Jr Scott and Sarah Kathryn Rouan. View Institutional Ownership Trends for Navidea Biopharmaceuticals.

NAVB stock was purchased by a variety of institutional investors in the last quarter, including Allred Capital Management LLC. Company insiders that have bought Navidea Biopharmaceuticals stock in the last two years include Claudine Bruck, Jed Latkin, John K Jr Scott and Sarah Kathryn Rouan. View Insider Buying and Selling for Navidea Biopharmaceuticals.

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NAVB stock can currently be purchased for approximately $0.98.

Navidea Biopharmaceuticals has a market capitalization of $17.72 million. Navidea Biopharmaceuticals employs 14 workers across the globe.View Additional Information About Navidea Biopharmaceuticals.

The official website for Navidea Biopharmaceuticals is http://www.navidea.com/.

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.